Skip to main content
Clinical Images

The First Two Cases of Long-Term Outcomes After Transcatheter Aortic Valve Replacement in Patients With Quadricuspid Aortic Valve

Dao Zhou, MD1;  Jiaqi Fan, MD1; Xianbao Liu, MD, PhD1*;  Jian’an Wang, MD, PhD1

October 2021
1557-2501
J INVASIVE CARDIOL 2021;33(10):E839-E840. doi:10.25270/jic/21.00140

Case Presentation

J INVASIVE CARDIOL 2021;33(10):E839-E840.

Key words: long-term outcomes, quadricuspid aortic valve, transcatheter aortic valve replacement


Case #1. A 79-year-old man was admitted to the hospital for severe aortic stenosis and moderate aortic regurgitation. A 4-leaflet, which was classified as a type E quadricuspid aortic valve (QAV),1 was found during the analysis of contrast-enhanced computed tomography (CT) images (Figures 1A, 1B, 1D). Transcatheter aortic valve replacement (TAVR) was then successfully performed with a 23 mm Venus A valve (Medtech). No abnormality of prosthesis was found at annual CT examination (Figures 1C, 1E). No major adverse cardiovascular events occurred during 5 years of follow-up until now.

Case #2. A type B QAV was found on CT in an 86-year-old man (Figures 1F, 1G, 1I). The TAVR procedure was successfully performed with a 26 mm Sapien XT valve (Edwards Lifesciences) for severe aortic stenosis and moderate-to-severe aortic regurgitation (Figures 1H, 1J). The patient was also free of major adverse cardiovascular events  during 3 years of follow-up.

Our study reported the first 2 cases of long-term outcome after TAVR in QAV. Neither valve structure deterioration nor major adverse cardiovascular events occurred in these 2 patients, suggesting a satisfactory long-term outcome. The first patient is the first reported case of TAVR in a type E QAV patient.

Affiliations and Disclosures

From the Department of Cardiology, Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China.

Disclosure: The authors have completed and returned the ICMJE Form for Disclosure of Potential Conflicts of Interest. The authors report no conflicts of interest regarding the content herein.

Manuscript accepted May 18, 2021.

The authors report patient consent for the images used herein.

Address for correspondence: Xianbao Liu, MD, PhD, Department of Cardiology, Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 310009, China. Email: liuxb@zju.edu.cn

References

1. Hurwitz LE, Roberts WC. Quadricuspid semilunar valve. Am J Cardiol. 1973;31:623-626.